<DOC>
	<DOCNO>NCT00078247</DOCNO>
	<brief_summary>This study design determine whether 6 month anti-HIV drug give along tuberculosis treatment delay onset AIDS HIV infect African patient .</brief_summary>
	<brief_title>Anti-HIV Drugs Ugandan Patients With HIV Tuberculosis</brief_title>
	<detailed_description>Tuberculosis ( TB ) common serious complication HIV infection develop world , especially sub-Saharan Africa . Since emergence HIV epidemic Africa , incidence rate TB rise dramatically , overwhelming national TB control program across continent . Over 50 % TB patient present TB clinic Africa HIV infect . These patient often present early stage HIV infection . Recent World Health Organization guideline management HIV-associated pulmonary TB recommend antiretroviral ( ARV ) therapy patient CD4 cell less 200 cells/mm3 , HIV infect TB patient present high CD4 count . In Uganda , half HIV infect patient active TB present TB clinic CD4 count 200 cells/mm3 , evidence coinfected patient high CD4 count treat ARV therapy . First , mortality HIV-associated TB high , even patient respond effective anti-tuberculosis therapy . Second , excess mortality associate TB evident CD4 count 200 cell/mm3 . Third , coinfected patient , TB result prolong immune activation , may enhance viral replication accelerate decline CD4 cell . This study evaluate whether short-term ARV therapy abacavir sulfate , lamivudine , zidovudine give treatment active TB slow progression HIV disease TB patient CD4 count least 350 cells/mm3 . The study also assess possible risk ( e.g. , drug toxicity resistance ) benefit ( e.g. , rapid clearance mycobacterium tuberculosis reduce TB relapse ) punctuate ARV therapy . Participants study HIV infect TB patient CD4 count least 350 cells/mm3 . All participant receive treatment TB . Participants randomly assign receive 6 month ARV therapy delay ARV therapy CD4 count drop 250 cells/mm3 . The participant follow 2 year ; CD4 count compare group . This study also follow group HIV infect patient without active TB quantify extent CD4 cell decline accelerate active TB determine extent decline neutralize patient receive punctuate ARV therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Diagnosis pulmonary TB ( AFB smearpositive culturepositive ) HIV infect CD4 count great 350 cells/mm3 Residence within 20 km Kampala , Uganda Willing use acceptable form contraception study 6 week stop study medication Parent guardian willing provide inform consent , applicable Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Africa</keyword>
</DOC>